Lustig A, Yofee A, Sokol R
Dept. of Pharmacy Services, Barzilai Medical Center, Ashkelon.
Harefuah. 1993 Sep;125(5-6):133-5, 192.
Problems associated with intravenous (IV) admixture preparation include contamination by microorganisms, human error and expense. To solve some of these problems, the Vialink system was developed by Travenol, Israel. This device enables enhanced sterility in clinical settings, since in the preparation of the admixture there is only a single penetration of the rubber seal of the vial. The dilution is performed immediately prior to administration, thereby reducing the possibility of wastage due to unused admixture. In addition, Vialink offers a means of double-checking the contents of the admixtures, since the emptied vial remains attached to the infusion bag. Results of our evaluation of this new system indicate that it offers substantial savings in preparation time and expense. It was suitable for 58.2% of all IV admixtures routinely hospital-prepared. The Vialink system may be a useful strategy, as it improves the quality of the service provided by the health service team and hospital pharmacists to their patients, and results in savings in budget and manpower.
静脉药物混合制剂的配制存在一些问题，包括微生物污染、人为失误和成本。为了解决其中一些问题，以色列特拉文诺尔公司开发了Vialink系统。该装置可提高临床环境中的无菌性，因为在配制混合制剂时，药瓶的橡胶密封仅被穿刺一次。稀释在给药前立即进行，从而减少了因未使用的混合制剂导致浪费的可能性。此外，Vialink提供了一种双重检查混合制剂内容物的方法，因为空药瓶仍与输液袋相连。我们对这个新系统的评估结果表明，它在配制时间和成本方面节省了大量费用。它适用于医院常规配制的所有静脉药物混合制剂的58.2%。Vialink系统可能是一种有用的策略，因为它提高了医疗服务团队和医院药剂师为患者提供的服务质量，并节省了预算和人力。
